CDK inhibitors in hormone receptor positive advanced breast cancer

Home Page
About
Submit A Journal
Submit A Conference
Submit Paper/Book
- Submit a Preprint
- Submit a Book
Contact

Marmara Medical Journal
Special Issue:1: Oncology Special Issue
CDK inhibitors in hormone receptor positive advanced breast cancer

CDK inhibitors in hormone receptor positive advanced breast cancer

Pages : 35-39

View : 57 | Download : 13

Publication Date : 2015-09-30

Article Type : Research Paper

Abstract :Endocrine treatment is the current first line treatment in ER+ advanced breast cancer with a requirement of predictive biomarkers to the treatment and different approaches for endocrine resistance risk. Cyclin dependent kinases insert ignore into journalissuearticles values(CDKs); are regulating each step of cellular division in mammalian cell cycle and are hyperactivated in cancer cells causing cancer progression. Next generation pan-CDK inhibitors are in clinical development, while clinical trials in breast cancer, particularly in ER+ subtype where the greatest growth inhibition has been observed. Here I will review the data from this new class of drugs. Keywords: CDK inhibitors, Hormone positive advanced breast cancer, Targeted therapies, Palbociclib, Endocrine therapy resistance
Keywords : CDK inhibitors, Hormone positive advanced breast cancer, Targeted therapies, Palbociclib, Endocrine therapy resistance

ORIGINAL ARTICLE URL

* There may have been changes in the journal, article,conference, book, preprint etc. informations. Therefore, it would be appropriate to follow the information on the official page of the source. The information here is shared for informational purposes. IAD is not responsible for incorrect or missing information.